

14th September 2017

Optiscan Appoints Exclusive China Distributor

Optiscan Imaging Limited (**Optiscan, the Company or OIL**) is pleased to announce the Exclusive Distribution Agreement with Chinese based China Gate Scientific (Shanghai) Co Ltd ("China Gate") for the latest Optiscan Preclinical Research system, ViewnVivo.

The Distribution Agreement has an initial term of 3 years with the option to extend for another 2 years. It provides for significant milestone orders and installations over this timeframe.

The appointment of China Gate represents a significant step forward and provides local representation in China with an organisation that has the market coverage, relationships, complementary product and service offerings and Preclinical Research industry experience, backed by deep technical capability, in one of the largest global markets for Optiscan.

Optiscan Chief Executive, Archie Fraser, said "We set out this year with a number of specific targets for the Company. One of our strategic goals was to position Optiscan and our technology into the market in China through the right partners. The appointment of China Gate is another important commercial advance into the global market".

China Gate was first established in Hong Kong in 2006, by John Coyle an Australian who now lives in China, to represent Western manufacturers of life and physical science equipment. China Gate is specifically structured to introduce new technology and instrumentation to a spectrum of life science and biomedical researchers in Greater China. Its customers include many of the top universities, research institutes and hospitals in the country, and continues to grow.

Optiscan will benefit from China Gate's market expertise, direct sales coverage, distribution and product support across the China Preclinical Research markets. It will take advantage from the fact that China Gate also sells other Preclinical Research product lines complementary to ViewnVivo.

John Coyle, Director of China Gate, will take responsibility for Optiscan's ViewnVivo preclinical products. Mr. Coyle commented, "We are honored to be involved in the introduction to China of Optiscan's ViewnVivo preclinical products. We share the same values in providing equipment of the highest technical excellence to researchers and securing their satisfaction with a commitment to comprehensive service".

Archie Fraser
Chief Executive Officer
E: afraser@optiscan.com

About ViewnVivo

ViewnVivo is Optiscan's latest miniaturised confocal endomicroscope technology platform for the Preclinical Research market. The unique and patented hand-held point scanning confocal imaging probe, enables In Vivo imaging not possible with any other technology or modality, with stunning sub-cellular resolution and automated Z-stacks to directly observe and capture systems biology for faster more complete research investigation. Researchers can now take the imaging to model rather than having to adapt the model for imaging.

About Optiscan

Optiscan is the world leader in the development and manufacture of high-resolution Miniaturised Confocal Endomicroscopes for Clinical and Preclinical Research markets.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

Phone (61 3) 9538 3333

Website www.optiscan.com

PO Box 1066, Mt Waverley MDC VIC 3149 Australia